➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Johnson and Johnson
McKesson
Harvard Business School
Dow

Last Updated: June 6, 2020

DrugPatentWatch Database Preview

NEULASTA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for NEULASTA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
BayerPhase 1
University of WashingtonPhase 1
Icahn School of Medicine at Mount SinaiPhase 1/Phase 2

See all NEULASTA clinical trials

Recent Litigation for NEULASTA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Amgen Inc. v. Accord BioPharma2018-08-07
Amgen Inc. v. Hospira, Inc.2018-07-18

See all NEULASTA litigation

Company Disclosures: US Patents for NEULASTA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX Orphan company
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-10 RX Orphan company
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for NEULASTA

These patents were identified by searching patent claims

Supplementary Protection Certificates for NEULASTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB03/006 United Kingdom   Start Trial PRODUCT NAME: PEGFILGRASTIM, AN N-TERMINALLY MONOPEGYLATED G-CSF (GRANULOCYTE COLONY STIMULATING FACTOR); REGISTERED: UK EU/1/02/228/001 20020826; UK EU/1/02/227/001 20020826
91006 Luxembourg   Start Trial
300106 Netherlands   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
2002C/040 Belgium   Start Trial PRODUCT NAME: PEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/02/227/001 20020823
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKesson
Mallinckrodt
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.